Thye Dirk
Known title: Chief Executive OfficerCIK: 0001638945
Thye Dirk's purchase track record
Thye Dirk has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/29/2024 | QNCX | $107K | +195.8% | +100.6% | +4.8% |
| 8/8/2023 | QNCX | $210K | -25.3% | +5.7% | +10.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| QNCX | ▼ Sell | Gift | 739,885 | $0 | 12/10/2025 | View on chart |
| QNCX | ▼ Sell | Gift | 739,885 | $0 | 12/10/2025 | View on chart |
| QNCX | ▲ Buy | Grant | 150,944 | $181K | 6/18/2025 | View on chart |
| QNCX | ▲ Buy | Open Market | 77,000 | $54K | 8/30/2024 | View on chart |
| QNCX | ▲ Buy | Open Market | 77,500 | $53K | 8/29/2024 | View on chart |
| QNCX | ▲ Buy | Option Exercise | 90,531 | $50K | 1/16/2024 | View on chart |
| QNCX | ▲ Buy | Option Exercise | 149,999 | $141K | 1/16/2024 | View on chart |
| QNCX | ▲ Buy | Open Market | 88,000 | $111K | 8/10/2023 | View on chart |
| QNCX | ▲ Buy | Open Market | 80,000 | $99K | 8/8/2023 | View on chart |
| QNCX | ▲ Buy | Grant | 64,589 | — | 5/19/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Quince Therapeutics LAM-001 Progress; Analyst Targets $70
Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.
Quince Therapeutics LAM-001 Progress; Analyst Targets $70. Quince Therapeutics reported progress on its LAM-001 program for pulmonary hypertension and bronchiolitis obliterans syndrome. A new analyst coverage was launched with a buy rating and a $70 price target. The company’s stock is trading near its 12‑touch support level of $17.70 and shows a moderate RSI of 55.9, indicating balanced momentum.